We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
+12.69%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$107M
AUM Growth
-$14.4M
Cap. Flow
-$401M
Cap. Flow %
-374.33%
Top 10 Hldgs %
58.32%
Holding
41
New
11
Increased
2
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
HELP
Cybin Inc
HELP
+$5.31M
2
ABVX
Abivax
ABVX
+$4.88M
3
CLSD
Clearside Biomedical
CLSD
+$3.73M
4
OTLK icon
Outlook Therapeutics
OTLK
+$2.52M
5
PYPD icon
PolyPid
PYPD
+$2.51M

Top Sells

Rank Stock Value
1
ATXS
Astria Therapeutics
ATXS
+$8.67M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$5.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.54M
4
CLRB icon
Cellectar Biosciences
CLRB
+$5M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$3.97M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPRB
26
Spruce Biosciences
SPRB
$119M
$1.19M 1.11%
20,112
-1,040
-5% -$264K
TLPH icon
27
Talphera
TLPH
$70.1M
$782K 0.73%
758,966
– –
BFRI icon
28
Biofrontera
BFRI
$15.7M
$777K 0.73%
+504,261
New +$699K
GERN icon
29
Geron
GERN
$860M
$660K 0.62%
200,000
– –
RZLT icon
30
Rezolute
RZLT
$470M
$510K 0.48%
+200,000
New +$285K
TNXP icon
31
Tonix Pharmaceuticals
TNXP
$161M
$168K 0.16%
282
– –
XBI icon
32
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$72.5K 0.07%
50,000
-450,000
-90% -$41.8M
QQQ icon
33
PUT
Invesco QQQ Trust
QQQ
$450B
$7K 0.01%
100,000
-800,000
-89% -$343M
ASND icon
34
Ascendis Pharma A/S
ASND
$16.5B
– –
-16,800
Closed -$2.12M
ATXS
35
DELISTED
Astria Therapeutics
ATXS
– –
-1,128,708
Closed -$8.67M
MDGL icon
36
Madrigal Pharmaceuticals
MDGL
$11.4B
– –
-25,000
Closed -$5.78M
NVNO
37
enVVeno Medical
NVNO
$7.1M
– –
-8,917
Closed -$1.6M
RVPH
38
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-9,815
Closed -$1.01M
SRPT icon
39
Sarepta Therapeutics
SRPT
$1.64B
– –
-57,400
Closed -$5.54M
SRPT icon
40
PUT
Sarepta Therapeutics
SRPT
$1.64B
– –
-57,400
Closed -$832K
MACK
41
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-60,000
Closed -$805K
1
2

Similar funds

TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return
SCM
Segra Capital Management Palm Beach, Florida $248M AUM 65.61% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return

Rosalind Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Rosalind Advisors held 41 positions worth $107M, down 12% from $121M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Rosalind Advisors withdrew a net $401M in Q1 2024, closing 8 positions and reducing 13 holdings. Its most notable exit was Astria Therapeutics, an estimated $8.67M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Rosalind Advisors opened a new position in Cybin Inc worth $5.77M.

  • Rosalind Advisors's largest Q1 2024 buy was Cybin Inc: 367,368 shares worth $5.77M.
  • Rosalind Advisors added most to Myomo in Q1 2024, an estimated $1.91M increase.
  • Rosalind Advisors's biggest Q1 2024 reduction was Cellectar Biosciences, cutting an estimated $5M.
  • Rosalind Advisors fully exited Astria Therapeutics in Q1 2024, selling an estimated $8.67M.
  • Rosalind Advisors's ten largest holdings make up 58% of its $107M portfolio in Q1 2024.
  • Rosalind Advisors opened 11 new positions and closed 8 in Q1 2024.
  • Rosalind Advisors's portfolio value fell 12% quarter-over-quarter to $107M.

Based on Rosalind Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.